litlas
Log inCreate account

Patrick J. Loehrer

Active 1984–2026

105
Papers
21,735
Citations
80
h-index
102
i10-index

Citations

Citations per year for Patrick J. Loehrer1985: 4 citations1986: 7 citations1987: 7 citations1988: 9 citations1989: 23 citations1990: 44 citations1991: 46 citations1992: 40 citations1993: 41 citations1994: 63 citations1995: 51 citations1996: 57 citations1997: 102 citations1998: 91 citations1999: 88 citations2000: 103 citations2001: 93 citations2002: 107 citations2003: 90 citations2004: 127 citations2005: 150 citations2006: 161 citations2007: 154 citations2008: 153 citations2009: 164 citations2010: 137 citations2011: 134 citations2012: 138 citations2013: 126 citations2014: 131 citations2015: 114 citations2016: 85 citations2017: 82 citations2018: 110 citations2019: 266 citations2020: 300 citations2021: 261 citations2022: 183 citations2023: 121 citations2024: 187 citations2025: 80 citations2026: 2 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,761 citing papers, 32.5% of this breakdownUnited Kingdom: 369 citing papers, 6.8% of this breakdownGermany: 350 citing papers, 6.5% of this breakdownItaly: 322 citing papers, 5.9% of this breakdownChina: 262 citing papers, 4.8% of this breakdownFrance: 253 citing papers, 4.7% of this breakdownJapan: 207 citing papers, 3.8% of this breakdownCanada: 204 citing papers, 3.8% of this breakdownNetherlands: 174 citing papers, 3.2% of this breakdownSpain: 152 citing papers, 2.8% of this breakdownAustralia: 106 citing papers, 2% of this breakdownBelgium: 103 citing papers, 1.9% of this breakdown
0%32.5%Other 21.3%

Institutions

Fields

  • Medicine81.3%
  • Biochemistry, Genetics and Molecular Biology12.6%
  • Immunology and Microbiology0.7%
  • Materials Science0.6%
  • Neuroscience0.5%
  • Social Sciences0.5%
  • Other3.8%

Topics

  • Testicular diseases and treatments4.2%
  • Colorectal Cancer Treatments and Studies3.7%
  • Myasthenia Gravis and Thymoma3.1%
  • Pancreatic and Hepatic Oncology Research2.5%
  • Bladder and Urothelial Cancer Treatments2.1%
  • Neuroblastoma Research and Treatments2%
  • Other82.4%

Coauthors

All papers

Open in search
  1. Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

    Authors: Patrick J. Loehrer, Yang Feng, Higinia R. Cárdenes, Lynne I. Wagner, Joanna M. Brell, David Cella, Patrick J. Flynn, Ramesh K. Ramanathan, Christopher H. Crane, Steven R. Alberts, Al B. Benson - Journal of Clinical Oncology 2011 cited by 832

  2. The Integrated Genomic Landscape of Thymic Epithelial Tumors

    Authors: Milan Radovich, Curtis R. Pickering, Ina Felau, Gavin Ha, Hailei Zhang, Heejoon Jo, Katherine A. Hoadley, Pavana Anur, Jiexin Zhang, Mike McLellan, Reanne Bowlby, Thomas Matthew, Ludmila Danilova, Apurva M. Hegde, Jaegil Kim, Mark D.M. Leiserson, Geetika Sethi, Charles Lu, Michael Ryan, Xiaoping Su, Andrew D. Cherniack, Gordon Robertson, Rehan Akbani, Paul T. Spellman, John N. Weinstein, D. Neil Hayes, Benjamin J. Raphael, Tara M. Lichtenberg, Kristen Leraas, Jean C. Zenklusen, Junya Fujimoto, Cristovam Scapulatempo‐Neto, André L. Moreira, David Hwang, James Huang, Mirella Marino, Robert J. Korst, Giuseppe Giaccone, Yesim Gökmen‐Polar, Sunil Badve, Arun Rajan, Philipp Ströbel, Nicolas Girard, Ming‐Sound Tsao, Alexander Marx, Anne S. Tsao, Patrick J. Loehrer, Adrian Ally, Elizabeth L. Appelbaum, J. Todd Auman, Miruna Balasundaram, Saianand Balu, Madhusmita Behera, Rameen Beroukhim, Mario Berríos, Giovanni Blandino, Tom Bodenheimer, Moiz S. Bootwalla, Jay Bowen, Denise Brooks, Flavio Mavignier Cárcano, Rebecca Carlsen, André Lopes Carvalho, Patricia Castro, Lara Chalabreysse, Lynda Chin, Juok Cho, Gina Choe, Eric Chuah, Sudha Chudamani, Carrie Cibulskis, Leslie Cope, Matthew G. Cordes, Daniel Crain, Erin Curley, Timothy Defreitas, John A. Demchok, Frank Detterbeck, Noreen Dhalla, Hendrik Dienemann, W. Jeff Edenfield, Francesco Facciolo, Martin L. Ferguson, Scott Frazer, Catrina C. Fronick, Lucinda A. Fulton, Robert S. Fulton, Stacey Gabriel, Johanna Gardner, Julie M. Gastier‐Foster, Nils Gehlenborg, Mark Gerken, Gad Getz, David I. Heiman, Shital Hobensack, Andrea Holbrook, Robert A. Holt, Alan P. Hoyle, Carolyn M. Hutter, Michael Ittmann and 88 more - Cancer Cell 2018 cited by 383

  3. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial

    Authors: Anish Thomas, Arun Rajan, Arlene Berman, Yusuke Tomita, Christina Brzezniak, Min-Jung Lee, Sunmin Lee, Alexander Ling, Aaron John Spittler, Corey A. Carter, Udayan Guha, Yisong Wang, Éva Szabó, Paul S. Meltzer, Seth M. Steinberg, Jane B. Trepel, Patrick J. Loehrer, Giuseppe Giaccone - The Lancet Oncology 2015 cited by 299

  4. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

    Authors: Patrick J. Loehrer, Lawrence H. Einhorn, Paul Elson, Emily Crawford, Philip Kuebler, Ian F. Tannock, Derek Raghavan, R. Stuart‐Harris, Michael F. Sarosdy, B A Lowe - Journal of Clinical Oncology 1992 cited by 987

  5. Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor

    Authors: Leonard B. Saltz, Neal J. Meropol, Patrick J. Loehrer, Michael N. Needle, Justin Kopit, Robert J. Mayer - Journal of Clinical Oncology 2004 cited by 1,703

  6. Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma

    Authors: G Lemma, Ju-Whei Lee, Seena C. Aisner, Corey J. Langer, William Tester, David H. Johnson, Patrick J. Loehrer - Journal of Clinical Oncology 2011 cited by 240

  7. Cisplatin

    Authors: Patrick J. Loehrer, LAWRENCE H. EINHORN - Annals of Internal Medicine 1984 cited by 951

  8. Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

    Authors: Giuseppe Giaccone, Arun Rajan, Arlene Berman, Ronan J. Kelly, Éva Szabó, Ariel López-Chávez, Jane B. Trepel, Min-Jung Lee, Liang Cao, Igor Espinoza‐Delgado, John Spittler, Patrick J. Loehrer - Journal of Clinical Oncology 2011 cited by 188

  9. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors

    Authors: Stuart Hinton, Paul J. Catalano, Lawrence H. Einhorn, Craig R. Nichols, E. David Crawford, Nicholas J. Vogelzang, Donald L. Trump, Patrick J. Loehrer - Cancer 2003 cited by 163

  10. Critical role of NF-κB in pancreatic cancer

    Authors: Lakshmi Prabhu, Rasika Mundade, Murray Korc, Patrick J. Loehrer, Tao Lu - Oncotarget 2014 cited by 146

  11. The National Cancer Institute–American Society of Clinical Oncology Cancer Trial Accrual Symposium: Summary and Recommendations

    Authors: Andrea Denicoff, Worta McCaskill‐Stevens, Stephen S. Grubbs, Suanna S. Bruinooge, Robert L. Comis, Peggy Devine, David M. Dilts, Michelle Duff, Jean G. Ford, Steven Joffe, Lidia Schapira, Kevin P. Weinfurt, Margo Michaels, Derek Raghavan, Ellen Richmond, Robin Zoň, Terrance L. Albrecht, Michael A. Bookman, Afshin Dowlati, Rebecca A. Enos, Mona N. Fouad, Marjorie J. Good, William J. Hicks, Patrick J. Loehrer, Alan P. Lyss, Steven N. Wolff, Debra Wujcik, Neal J. Meropol - Journal of Oncology Practice 2013 cited by 142

  12. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer

    Authors: Eric Van Cutsem, R. Mayer, Stéphanie Laurent, Robert Winkler, Cristina Grávalos, Manuel Benavides, Federico Longo-Muñoz, Fabienne Portales, Fortunato Ciardiello, Salvatore Siena, Kensei Yamaguchi, Kei Muro, Tadamichi Denda, Yasushi Tsuji, Lukas Makris, Patrick J. Loehrer, Heinz‐Josef Lenz, Atsushi Ohtsu - European Journal of Cancer 2017 cited by 99

  13. A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.

    Authors: Safi Shahda, Anne M. Noonan, Tanios Bekaii‐Saab, Bert H. O’Neil, Amikar Sehdev, Walid L. Shaib, Paul R. Helft, Patrick J. Loehrer, Yan Tong, Ziyue Liu, Bassel F. El‐Rayes - Journal of Clinical Oncology 2017 cited by 77

  14. Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide

    Authors: Stephen D. Williams, Robert Birch, Lawrence H. Einhorn, Linda Irwin, F. Anthony Greco, Patrick J. Loehrer - New England Journal of Medicine 1987 cited by 1,182

  15. The development of non-germ cell malignancies within germ cell tumors. A clinicopathologic study of 11 cases

    Authors: Thomas M. Ulbright, Patrick J. Loehrer, Lawrence M. Roth, Lawrence H. Einhorn, Stephen D. Williams, Steven A. Clark - Cancer 1984 cited by 371

  16. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.

    Authors: Craig R. Nichols, Paul J. Catalano, Emily Crawford, N. Vogelzang, Lawrence H. Einhorn, Patrick J. Loehrer - Journal of Clinical Oncology 1998 cited by 347

  17. Cisplatin as first-line therapy for metastatic breast cancer.

    Authors: George W. Sledge, Patrick J. Loehrer, Bruce J. Roth, L H Einhorn - Journal of Clinical Oncology 1988 cited by 224

  18. Octreotide Alone or With Prednisone in Patients With Advanced Thymoma and Thymic Carcinoma: An Eastern Cooperative Oncology Group Phase II Trial

    Authors: Patrick J. Loehrer, Wei Wang, David H. Johnson, David S. Ettinger - Journal of Clinical Oncology 2004 cited by 205

  19. A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker

    Authors: Linda H. Malkas, Brittney-Shea Herbert, Waleed Abdel‐Aziz, Lacey E. Dobrolecki, Yang Liu, Beamon Agarwal, Derek J. Hoelz, Sunil Badve, Lauren A. Schnaper, Randy J. Arnold, Yehia Mechref, Miloš V. Novotný, Patrick J. Loehrer, Robert J. Goulet, Robert J. Hickey - National Academy of Sciences, Proceedings of the National Academy of Sciences 2006 cited by 135

  20. Postoperative Radiotherapy After Surgical Resection of Thymoma: Differing Roles in Localized and Regional Disease

    Authors: Jeffrey A. Forquer, Nan Rong, Achilles J. Fakiris, Patrick J. Loehrer, Peter A.S. Johnstone - International Journal of Radiation Oncology*Biology*Physics 2009 cited by 124

  21. Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

    Authors: Michael Sangmin Lee, Patrick J. Loehrer, Iman Imanirad, Stacey A. Cohen, Kristen K. Ciombor, Dominic T. Moore, Cheryl A. Carlson, Hanna K. Sanoff, Autumn J. McRee - Journal of Clinical Oncology 2021 cited by 44

  22. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.

    Authors: Patrick J. Loehrer, R Gonin, Craig R. Nichols, Trenna Weathers, Lawrence H. Einhorn - Journal of Clinical Oncology 1998 cited by 401

  23. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.

    Authors: Patrick J. Loehrer, KyungMann Kim, Seena C. Aisner, Robert B. Livingston, Lawrence Einhorn, David H. Johnson, Rob Blum - Journal of Clinical Oncology 1994 cited by 308

  24. Standard Outcome Measures for Thymic Malignancies

    Authors: James Huang, Frank Detterbeck, Zuoheng Wang, Patrick J. Loehrer - Journal of Thoracic Oncology 2010 cited by 212